Collegium reports record Q4 revenue $181.9M, GAAP EPS $0.36; EVP Shirley Kuhlmann departing March 7

COLLEGIUM PHARMACEUTICAL, INC

2024-FY EPS reported $1.86 revenue$631,449,000

Q4 product revenue $181.9M (+22% YoY); GAAP net income $12.5M ($0.36 diluted EPS); adjusted EBITDA $107.7M.
FY2024 product revenue $631.4M (+11% YoY); GAAP net income $69.2M ($1.86 diluted EPS); adjusted EBITDA $401.2M.
Jornay PM pro forma FY2024 net rev $100.7M; expects >$135M in 2025. Belbuca Q4 net rev $55.2M (+12% YoY); Xtampza ER $51.5M (+6% YoY).
Reaffirmed FY2025 guidance: product revenue $735-750M, adj EBITDA $435-450M. Repurchased $60M in shares in 2024; cash $162.8M.
EVP, Chief Admin Officer, General Counsel & Secretary Shirley Kuhlmann stepping down effective March 7, 2025; treated as termination without cause.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Shirley Kuhlmann

Executive Vice President, Chief Administrative Officer, General Counsel & Secretary

COLL · COLLEGIUM PHARMACEUTICAL, INC

Effective: 2025-03-07
Filed: February 27, 2025, 6:59 PM ET

On February 27, 2025, the Company announced that Shirley Kuhlmann, Executive Vice President, Chief Administrative Officer, General Counsel & Secretary of the Company will step down from her positions at the Company effective March 7, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shirley Kuhlmann departed as Executive Vice President, Chief Administrative Officer, General Counsel & Secretary at COLLEGIUM PHARMACEUTICAL, INC.

Action: stepping down
Role: Executive Vice President, Chief Administrative Officer, General Counsel & Secretary

Exact text from the filing

On February 27, 2025, the Company announced that Shirley Kuhlmann, Executive Vice President, Chief Administrative Officer, General Counsel & Secretary of the Company will step down from her positions at the Company effective March 7, 2025.

View on SEC.gov

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001558370-25-001799

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.